Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis (IVAS)
Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis
Sponsor: American University of Beirut Medical Center
Listed as NCT02706704, this PHASE2 trial focuses on Non-Infectious Uveitis and Uveitis and remains actively recruiting participants. Sponsored by American University of Beirut Medical Center, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2021 — Aug 2023 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American University of Beirut Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .